FNFatta B. Nahab

Fatta B. Nahab

*This is an algorithmically generated author record based on publicly available information.

Fatta B. Nahab has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Powering Neurology Drug Development Trials to Reduce False Negative Results

    by Hiromasa Mori, Stig Johan Wiklund, Vikram Ramanarayanan, Fatta B. Nahab

    Sensitive and reliable measurement of therapeutic outcomes in neurology drug trials remains challenging. Clinical rating scales and their total scores are often considered the gold standard and used as primary efficacy endpoints in studies because of their acceptance by the clinical community and regulators. However, rating scales have limitations when used in drug development, and we hypothesize that their lower statistical power is one possible reason leading to false negative results. This paper proposes a framework to address four systemic components of statistical power—size of the treatment effect, variability, sample size, and statistical threshold—to minimize the odds of observing false negatives, and thereby maximize the odds of trial success. Drawing from the literature and biopharmaceutical anecdotal evidence, we identify key factors that affect each of these power components and assess their influence. We also highlight challenges with rating scale endpoints associated with total scores and large sample sizes. We identify potential causes of rating scale endpoint failure and provide an indication‐agnostic framework for understanding the relationship between clinical rating scale performance and study power. The proposed methods can be applied to both study design and post hoc analysis.


  • Open Access

    Double-Blind, Randomized, Placebo-Controlled, Crossover Study of Oral Cannabidiol and Tetrahydrocannabinol for Essential Tremor

    by Katherine Longardner, Qian Shen, Francisco X. Castellanos, Bin Tang, Rhea Gandhi, Brenton A. Wright, Jeremiah D. Momper, Fatta B. Nahab

    Background: Essential tremor (ET) is characterized by often disabling action tremors. No pharmacological agent has been developed specifically for symptomatic treatment. Anecdotal reports describe tremor improvement with cannabis, but no evidence exists to support these claims. We conducted a phase Ib/II double-blind, placebo-controlled, crossover pilot trial in participants with ET to investigate tolerability, safety, and efficacy of Tilray TN-CT120 LM, an oral pharmaceutical-grade formulation containing tetrahydrocannabinol (THC) 5 mg and cannabidiol (CBD) 100 mg. Our objectives were to determine if short-term THC/CBD exposure improved tremor amplitude and was tolerated. Methods: Participants with ET were randomized (1:1) to receive either TN-CT120 LM or placebo. Dose titration, driven by tolerability, was attempted every 2–3 days to three capsules daily maximum. Participants remained on the highest tolerated dose for two weeks before returning to complete assessments. After completing the first arm, participants titrated off the agent, underwent a three-week washout, and then returned for the same procedures with the alternate compound. The primary endpoint was tremor amplitude change from baseline using digital spiral assessment. Secondary endpoints explored safety and tolerability. Results: Among thirteen participants screened, seven were eligible and enrolled. Five completed all visits; one withdrew following a serious adverse event, and another did not tolerate the lowest dose. Intent-to-treat analyses performed for six participants did not reveal significant effects on primary or secondary endpoints. Conclusions: This pilot trial did not detect any signals of efficacy of THC/CBD in ET. Although preliminary due to the small sample size, our data do not support anecdotal reports of cannabinoid effectiveness for ET. Highlights This double-blind, randomized, placebo-controlled efficacy and tolerability pilot trial did not detect any signals of efficacy of oral cannabidiol and tetrahydrocannabinol in reducing essential tremor amplitude using either digital outcome measures or clinical rating scales. The oral cannabinoids were well-tolerated by most (five out of seven) participants.

  • Open Access

    An Algorithm for Automated Measurement of Kinetic Tremor Magnitude Using Digital Spiral Drawings

    by Katherine Longardner, Qian Shen, Bin Tang, Brenton A. Wright, Prantik Kundu, Fatta B. Nahab

    Introduction: Essential tremor is a common movement disorder. Numerous validated clinical rating scales exist to quantify essential tremor severity by employing rater-dependent visual observation but have limitations, including the need for trained human raters and the lack of precision and sensitivity compared to technology-based objective measures. Other continuous objective methods to quantify tremor amplitude have been developed, but frequently provide unitless measures (e.g., tremor power), limiting real-world interpretability. We propose a novel algorithm to measure kinetic tremor amplitude using digital spiral drawings, applying the V3 framework (sensor verification, analytical validation, and clinical validation) to establish reliability and clinical utility. Methods: Archimedes spiral drawings were recorded on a digitizing tablet from participants (n = 7) enrolled in a randomized placebo control double-blinded crossover pilot trial evaluating the efficacy of oral cannabinoids in reducing essential tremor. We developed an algorithm to calculate the mean and maximum tremor amplitude derived from the spiral tracings. We compared the digitally measured tremor amplitudes to manual measurement to evaluate sensor reliability, determined the test-retest reliability of the digital output across two short-interval repeated measures, and compared the digital measure to kinetic tremor severity graded using The Essential Tremor Rating Assessment Scale (TETRAS) score for spiral drawings. Results: This algorithm for automated assessment of kinetic tremor amplitude from digital spiral tracings demonstrated a high correlation with manual spot measures of tremor amplitude, excellent test-retest reliability, and a high correlation with human ratings of the TETRAS score for spiral drawing severity when the tremor severity was rated “slight tremor” or worse. Discussion: This digital measure provides a simple and clinically relevant evaluation of kinetic tremor amplitude that shows promise as a potential future endpoint for use in clinical trials of essential tremor.


  • Physiological and introspective antecedents of tics and movements in adults with tic disorders

    by Antonio I. Triggiani, Kaya Scheman, Sarah Pirio Richardson, Masao Matsuhashi, Elizabeth Peckham, Fatta Nahab, Zoltan Mari, Shashi Ravindran, Mark Hallett


  • Open Access

    Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis

    by Katherine Longardner, Brenton A Wright, Aljoharah Alakkas, Hyeri You, Ronghui Xu, Lin Liu, Fatta B Nahab

    Background: Parkinson disease (PD) psychosis (PDP) is a disabling non-motor symptom. Pharmacologic treatment is limited to pimavanserin, quetiapine, and clozapine, which do not worsen parkinsonism. A Food and Drug Administration black box warning exists for antipsychotics, suggesting increased mortality in elderly patients with dementia. However, the reasons for higher mortality are unknown. Aim: Expanding on prior work exploring mortality in treated PDP patients, we conducted a retrospective comparison to understand the links between treatment regimen, clinical characteristics, and negative outcomes. Methods: Electronic medical record data extraction included clinically diagnosed PD patients between 4/29/16-4/29/19 and excluded patients with primary psychiatric diagnoses or atypical parkinsonism. Mortality and clinical characteristics during the study period were compared between untreated patients and those receiving pimavanserin, quetiapine, or both agents (combination). Mortality analyses were adjusted for age, sex, levodopa equivalent daily dose (LEDD), and dementia. Results: The pimavanserin group (n = 34) had lower mortality than the untreated group (n = 66) (odds ratio = 0.171, 95% confidence interval: 0.025–0.676, p = 0.026). The untreated group had similar mortality compared to the quetiapine (n = 147) and combination (n = 68) groups. All treated groups had a higher LEDD compared to the untreated group, but no other differences in demographics, hospitalizations, medical comorbidities, medications, or laboratory values were found between the untreated and treated groups. Conclusions: PDP patients receiving pimavanserin had lower mortality than untreated patients. We found no other clear differences in clinical characteristics to explain the mortality risk. Prospective randomized trials are needed to definitively identify the optimal PDP treatment regimen and associated risks.


  • Open Access

    Improving Medication Regimen Recommendation for Parkinson’s Disease Using Sensor Technology

    by Jeremy Watts, Anahita Khojandi, Rama Vasudevan, Fatta B. Nahab, Ritesh A. Ramdhani

    Parkinson’s disease medication treatment planning is generally based on subjective data obtained through clinical, physician-patient interactions. The Personal KinetiGraph™ (PKG) and similar wearable sensors have shown promise in enabling objective, continuous remote health monitoring for Parkinson’s patients. In this proof-of-concept study, we propose to use objective sensor data from the PKG and apply machine learning to cluster patients based on levodopa regimens and response. The resulting clusters are then used to enhance treatment planning by providing improved initial treatment estimates to supplement a physician’s initial assessment. We apply k-means clustering to a dataset of within-subject Parkinson’s medication changes—clinically assessed by the MDS-Unified Parkinson’s Disease Rating Scale-III (MDS-UPDRS-III) and the PKG sensor for movement staging. A random forest classification model was then used to predict patients’ cluster allocation based on their respective demographic information, MDS-UPDRS-III scores, and PKG time-series data. Clinically relevant clusters were partitioned by levodopa dose, medication administration frequency, and total levodopa equivalent daily dose—with the PKG providing similar symptomatic assessments to physician MDS-UPDRS-III scores. A random forest classifier trained on demographic information, MDS-UPDRS-III scores, and PKG time-series data was able to accurately classify subjects of the two most demographically similar clusters with an accuracy of 86.9%, an F1 score of 90.7%, and an AUC of 0.871. A model that relied solely on demographic information and PKG time-series data provided the next best performance with an accuracy of 83.8%, an F1 score of 88.5%, and an AUC of 0.831, hence further enabling fully remote assessments. These computational methods demonstrate the feasibility of using sensor-based data to cluster patients based on their medication responses with further potential to assist with medication recommendations.


  • Open Access

    How Do I Assess Tremor Using Novel Technology?

    by Katherine Longardner, Felipe Vial Undurraga, Fatta B. Nahab, Mark Hallett, Dietrich Haubenberger

    Transducers are defined as any sensor that converts a physiological signal of tremor into an electrical signal. Evolving technologies have utilized transducers to develop devices for tremor measurement that are more convenient, accurate, and capable of continuous recording. Transducer‐based methods provide valuable diagnostic tools for the clinician that can distinguish between different tremor syndromes and differentiate tremor from other hyperkinetic movement disorders. Transducers are also used to objectively quantify and track tremor symptom severity over time and assess clinical response to intervention (e.g., pharmaceutical treatments or DBS). This video highlights the utility of transducer‐based methods in characterizing and quantifying tremor and reviews the available technologies for measuring tremor. We provide case examples that demonstrate how different technology‐based measures for tremor direct the approach to diagnosis and management of symptoms.


  • Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine

    by Gabriel M. Moreno, Rhea Gandhi, Stephanie L. Lessig, Brenton Wright, Irene Litvan, Fatta B. Nahab


  • Open Access

    Impaired sense of agency in functional movement disorders: An fMRI study

    by Fatta B Nahab, Prantik Kundu, Carine Maurer, Qian Shen, Mark Hallett

    The sense of agency (SA) is an established framework that refers to our ability to exert and perceive control over our own actions. Having an intact SA provides the basis for the human perception of voluntariness, while impairments in SA are hypothesized to lead to the perception of movements being involuntary that may be seen many neurological or psychiatric disorders. Individuals with functional movement disorders (FMD) experience a lack of control over their movements, yet these movements appear voluntary by physiology. We used fMRI to explore whether alterations in SA in an FMD population could explain why these patients feel their movements are involuntary. We compared the FMD group to a control group that was previously collected using an ecologically valid, virtual-reality movement paradigm that could modulate SA. We found selective dysfunction of the SA neural network, whereby the dorsolateral prefrontal cortex and pre-supplementary motor area on the right did not respond differentially to the loss of movement control. These findings provide some of the strongest evidence to date for a physiological basis underlying these disabling disorders.